EGFR-IN-151

EGFR-IN-151 (Compound 10) inhibits EGFR and its downstream signaling pathways ERK/STAT3. EGFR-IN-151 inhibits the proliferation of a variety lung cancer cells (IC50s for NCI-H1781, HCC827, NCI-H3255 and NCI-H1975 is 11.7, 5.19, 7.32 and 1.53 μM, respectively), inhibits the colony formation and migration of H1975, arrests the cell cycle at G1 phase, and induces apoptosis in H1975[1].

Product Specifications

UNSPSC

12352005

Target

Apoptosis; EGFR; ERK; STAT

Related Pathways

Apoptosis; JAK/STAT Signaling; MAPK/ERK Pathway; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Smiles

O=C(O[C@H]1[C@@H](C2=CC(O)=C(O)C(O)=C2)OC3=C(C(OCC4=CN(CCOCCOCCOCCN5N=NC(C6=CC=CC(NC7=C8C=C(OCCOC)C(OCCOC)=CC8=NC=N7)=C6)=C5)N=N4)=CC(O)=C3)C1)C9=CC(O)=C(O)C(O)=C9

Molecular Formula

C55H59N9O18

Molecular Weight

1134.11

References & Citations

[1]Zi CT, et al. Novel (-) -eigallocatechin-3-gallate-erlotinib conjugates via triazole rings inhibit non-small cell lung cancer cells through EGFR signaling pathway. Bioorg Chem. 2025 Apr;157:108263.